Postmenopausal Osteoporosis: Clinical Guide on Selective Estrogen Receptor Modulators

by Kathy Jones on  March 2, 2012 at 8:55 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas has been announced by Elsevier, a world-leading provider of scientific, technical and medical information products and services.
 Postmenopausal Osteoporosis: Clinical Guide on Selective Estrogen Receptor Modulators
Postmenopausal Osteoporosis: Clinical Guide on Selective Estrogen Receptor Modulators

This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene and lasofoxifene.

Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. Various therapies such as bisphosphonates, strontium ranelate and more recently denomsumab are available but these are not suitable for all women. Health concerns have been raised resulting from these therapies, such as oesophageal cancer, osteonecrosis of the jaw (ONJ) and subtrochanteric fractures with bisphosphonates and venous thromboembolism with strontiumranelate. Use of bazedoxifene and lasofoxifene will increase the number of therapeutic options available as these new SERMs point to a greater anti-fracture potential.

The decision of which type of treatment to use for osteoporosis and when to begin should be based on the need to reduce fracture risk. All treatments including SERMs should include recommendations for a healthy life style and adequate calcium and vitamin D intake. Additional benefits of different agents (i.e. climacteric symptom improvement with estrogens, breast cancer prevention for SERMS) must be considered when selecting the anti-osteoporosis drug. Furthermore what agent is used (estrogen, SERM, bisphosphonates) may vary over a woman's life time. The clinical guide from the European Menopause and Andropause Society (EMAS) details all important and necessary aspects of consideration.



Source: Eurekalert

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Menopause Dilatation and Curettage Oophorectomy Hormone Replacement Therapy Dealing with Menopause symptoms through lifestyle changes Estrogen Dominance 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive